RecruitingPhase 2NCT05575505
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Sponsor
Tanta University
Enrollment
44 participants
Start Date
Feb 2, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon cancer, so there is a continuous need for introducing new therapies that decrease progression, and hence better outcomes
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria3
- Age ≥ 18 years
- Both males and females will be included
- Negative pregnancy test and effective contraception.
Exclusion Criteria7
- Breastfeeding
- Significant liver and kidney function abnormalities
- Colorectal cancer patients
- Patients with severe UC
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
- Addiction to alcohol and / or drugs
Interventions
DRUGPentoxifylline 400 MG
Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05575505
Related Trials
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395126 locations
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883159 locations
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT0484460663 locations
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
NCT012808251 location
Fermented Food-Supplemented Diet in Ulcerative Colitis
NCT044016051 location